1. Scrip

Could Prevention Data Give REGEN-COV Competitive Leg Up?

 
• By Alaric DeArment

Could Prevention Data Give REGEN-COV Competitive Leg Up?

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
Regeneron announced data on the monoclonal antibody cocktail REGEN-COV showing long-term protection against COVID-19 • Source: Shutterstock

Data showing Regeneron Pharmaceuticals, Inc./Roche Holding AG’s REGEN-COV (casirivimab/imdevimab) has strong efficacy in preventing COVID-19 with one dose may give the antibody cocktail an advantage on the market for drugs to prevent COVID-19 despite concerns about its long-term market durability due to looming competition from oral therapies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.